Fingerprint
Dive into the research topics where Aðalgeir Arason is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Genome-wide association study of 398,238 women unveils seven loci associated with high-grade serous ovarian cancer
Barnes, D. R., Tyrer, J. P., Dennis, J., Leslie, G., Bolla, M. K., Lush, M., Aeilts, A. M., Aittomäki, K., Andrieu, N., Andrulis, I. L., Anton-Culver, H., Arason, A., Arun, B. K., Balmaña, J., Bandera, E. V., Barkardottir, R. B., Berger, L. P. V., Berrington de Gonzalez, A., Berthet, P. & Białkowska, K. & 148 others, , Dec 2025, In: npj Genomic Medicine. 10, 1, p. 73 73.Research output: Contribution to journal › Article › peer-review
Open Access -
A Breast Cancer Candidate Locus at 6q Narrowed to 6q15-q21
Csuka, D., Freysteinsdóttir, E. S., Jóhannesdóttir, G., Agnarsson, B. A., Jóhannsson, Ó. Þ., Barkardóttir, R. B. & Arason, A., 8 Feb 2024, In: Genes. 15, 2, 6 p., 218.University of Iceland, Landspitali
Research output: Contribution to journal › Article › peer-review
Open Access -
Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk
GEMO Study Collaborators, Arason, A. & Barkardóttir, R. B., 4 Mar 2024, (Submitted) In: medRxiv : the preprint server for health sciences.Research output: Contribution to journal › Article
-
High Atlastin 2-2 (ATL2-2) Expression Associates with Worse Prognosis in Estrogen-Receptor-Positive Breast Cancer
Reynisdóttir, I., Arason, A., Freysteinsdóttir, E. S., Kristjánsdóttir, S. B., Hilmarsdóttir, B., Traustadóttir, G. Á., Jóhannsson, Ó. Þ., Agnarsson, B. A. & Barkardóttir, R. B., Aug 2023, In: Genes. 14, 8, 1559.Landspitali, University of Iceland
Research output: Contribution to journal › Article › peer-review
Open Access -
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
AOCS Group, CZECANCA Consortium, The Consortium of Investigators of Modifiers of BRCA1/2, Evidence-based Network for the Interpretation of Germline Mutant Alleles Consortium, HEBON Investigators, GEMO Study Collaborators & Arason, A., Jun 2023, In: British Journal of Cancer. 128, 12, p. 2283-2294 12 p.Research output: Contribution to journal › Article › peer-review
Open Access